Vertebral Technologies, Inc. Announces 500 th Implant of the InterFuse® Interbody Fusion Device

Minneapolis, January 6, 2010 Vertebral Technologies, Inc. (VTI), a Minnetonka, MN based spinal implant manufacturer announced a major milestone in the commercialization of the InterFuse ® Interbody Fusion Device. On December 23 rd , the 500 th InterFuse Device was implanted using VTI’s patented Intraoperative Assembly™ technology, which allows the surgeon to assemble a large implant through a minimally invasive surgical approach. The Unilateral Posterior Lumbar Interbody Fusion (UPLIF ® ) procedure uses a single posterior incision to access the disc, reducing tissue dissection and nerve root retraction while preserving the facet joints. VTI continues to expand commercial distribution of the InterFuse Interbody Fusion System throughout the United States.

Gregory D. Carlson, M.D. of Orthopaedic Specialty Institute of Orange County in Orange, California said, “The InterFuse Interbody Fusion System allows me to treat patients using a minimally invasive posterior surgical approach to the spine and implant a
larger fusion device than is possible with other systems. This combination offers my patients better fusion outcomes while significantly reducing postoperative pain.”

Jeffrey Felt, M.D., Chief Executive Officer of VTI, comments, “Achievement of this milestone less that 16 months after introduction demonstrates the rapid adoption of the Interfuse Interbody Fusion System and validates our Intraoperative Assembly approach to
implanting large devices through minimal access surgery. VTI continues to develop this concept for surgical approaches using both fusion and nonfusion devices, particularly the InterCushion® Disc Nucleus Replacement Device.”

About Vertebral Technologies, Inc.

Vertebral Technologies has pioneered Intraoperative Assembly technology which enables
spine surgeons to implant large, customized devices in the intervertebral disc space. This
technology platform is being adapted for a number of spinal implant applications. The
Company’s first two products are the InterFuse Interbody Fusion System, which has been
available for sale in the U.S. since 2008 and the InterCushion® Disc Nucleus
Replacement, which will begin human clinical testing in 2010.


Josh Sandberg

Josh Sandberg is the President of Ortho Spine Partners and Partner for The De Angelis Group. He also serves as Co-Founder and Editor of OrthoSpineNews.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button